Copertina

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jian Wang, Shaoqiu Zhang, Zhiyi Zhang, Chao Wu, Rui Huang
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
di: Jian Wang, et al.
Pubblicazione: (2024)

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
di: Lisa Sandmann, et al.
Pubblicazione: (2024)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
di: Jian Wang, et al.
Pubblicazione: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
di: Zhuo Li, et al.
Pubblicazione: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
di: Stuart McPherson, et al.
Pubblicazione: (2024)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
di: Jian Wang, et al.
Pubblicazione: (2025)

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
di: Lukas Hartl, et al.
Pubblicazione: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
di: Mingsi Zhang, et al.
Pubblicazione: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
di: Jannis Kountouras, et al.
Pubblicazione: (2024)

Racial and ethnic disparities in post‐liver transplant outcomes for patients with acute‐on‐chronic liver failure: An analysis of the UNOS database
di: David Uihwan Lee, et al.
Pubblicazione: (2024)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed
di: Haibo Jing, et al.
Pubblicazione: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
di: Mohamed I. Elsaid, et al.
Pubblicazione: (2024)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
di: Ivan Arcari, et al.
Pubblicazione: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
di: Yaomin Wang, et al.
Pubblicazione: (2024)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
di: Rui Zhang, et al.
Pubblicazione: (2024)

Review article: Oesophageal disorders in chronic liver disease
di: Francisco Idalsoaga, et al.
Pubblicazione: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
di: Hyeyeon Hong, et al.
Pubblicazione: (2024)

Letter: Enhancing patient support through social work—Addressing economic challenges and medication non‐adherence in liver disease management
di: Min Wu, et al.
Pubblicazione: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
di: Elliot B. Tapper, et al.
Pubblicazione: (2024)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply
di: Andrea Martini, et al.
Pubblicazione: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B
di: Jing Li, et al.
Pubblicazione: (2024)

Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find
di: Leya Nedumannil, et al.
Pubblicazione: (2024)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
di: Wenjun Meng, et al.
Pubblicazione: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
di: Chen‐Pi Li, et al.
Pubblicazione: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
di: Nabil Noureddin, et al.
Pubblicazione: (2024)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
di: Nina Dominik, et al.
Pubblicazione: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
di: Lukas Burghart, et al.
Pubblicazione: (2024)

Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find. Author's reply
di: Sagnik Biswas, et al.
Pubblicazione: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients
di: Ming‐Lun Yeh, et al.
Pubblicazione: (2024)

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease
di: Jannis Kountouras, et al.
Pubblicazione: (2024)

Letter: Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection
di: Jianrong Li, et al.
Pubblicazione: (2024)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
di: Eiichi Ogawa
Pubblicazione: (2024)

Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection
di: Na‐Ling Kang, et al.
Pubblicazione: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
di: Sung Won Chung, et al.
Pubblicazione: (2024)

Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis
di: Shusuke Kumazaki, et al.
Pubblicazione: (2024)

Duke Activity Status Index and Liver Frailty Index predict mortality in ambulatory patients with advanced chronic liver disease: A prospective, observational study
di: Felicity R. Williams, et al.
Pubblicazione: (2024)

Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance
di: Senlin Ye, et al.
Pubblicazione: (2024)

Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial
di: Elliot B. Tapper, et al.
Pubblicazione: (2024)

Review article: Evaluation and care of the critically ill patient with cirrhosis
di: Iva Kosuta, et al.
Pubblicazione: (2024)